Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NOVARTIS TO ACQUIRE REGULUS FOR $7.00 PER SHARE IN CASH, WITH POTENTIAL TO RECEIVE AN ADDITIONAL $7.00 PER SHARE IN CASH THROUGH A CONTINGENT VALUE RIGHT, FOR A TOTAL EQUITY VALUE OF UP TO APPROXIMATELY $1.7 BILLION TRANSACTION IS EXPECTED TO BE COMPLETED IN THE SECOND HALF OF 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS SAN DIEGO , APRIL 30, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT AND PLAN OF MERGER WITH NOVARTIS AG ("NOVARTIS") AND AN INDIRECTLY WHOLLY OWNED SUBSIDIARY OF NOVARTIS, PURSUANT TO WHICH NOVARTIS WILL ACQUIRE REGULUS FOR AN INITIAL PAYMENT OF $7.00 PER SHARE IN CASH AT CLOSING, OR $0.8 BILLION. THE UPFRONT CASH PORTION OF THE CONSIDERATION REPRESENTS A PREMIUM OF 274 PERCENT TO REGULUS' 60-DAY VOLUME-WEIGHTED AVERAGE STOCK PRICE AND 108 PERCENT TO REGULUS' CLOSING PRICE ON APRIL 29, 2025.

REGULUS THERAPEUTICS ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG

SAN DIEGO , APRIL 2, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT JAY HAGAN, CEO, WILL PARTICIPATE IN A PRESENTATION AT THE 2025 OPPENHEIMER INNOVATION ON THE ISLAND BIOTECH SUMMIT ON WEDNESDAY, APRIL 9 TH AT 11:32 A.M. ET. THE LIVE EVENT AND REPLAY OF THE PRESENTATION WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" THROUGH THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.REGULUSRX.COM/EVENTS AND ARCHIVED FOR 90 DAYS FOLLOWING THE PRESENTATION DATE.

REGULUS THERAPEUTICS TO PRESENT AT THE 2025 OPPENHEIMER INNOVATION ON THE ISLAND BIOTECH SUMMIT

POSITIVETOPLINE DATA FROM THE FOURTH COHORT OF PATIENTS CONSISTENT DEMONSTRATION OFPOLYCYSTIN (PC) BIOMARKER IMPACT CONFIRMING 300 MG FIXED DOSE SELECTION TO ACHIEVE OPTIMAL KIDNEY EXPOSURE PATIENTS RECEIVING 300 MGFARABURSEN DEMONSTRATED A MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME (HTTKV) GROWTH OVER 4 MONTHS EXPLORATORY ANALYSIS OF PATIENTS FROM HIGH-DOSE COHORTS DEMONSTRATES STATISTICAL SIGNIFICANCE INHTTKV CHANGE COMPARED TO A LARGE COHORT OF HISTORICAL PLACEBO-TREATED PATIENTS, WHICH MEANINGFULLY DERISKS THE 12-MONTH HTTKV ENDPOINT IN THE PLANNED PHASE 3 TRIAL COMPANY ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN THIRD QUARTER 2025 SAN DIEGO , MARCH 27, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ALL PATIENTS IN THE FOURTH COHORT IN ITS PHASE 1B MAD STUDY OF FARABURSEN FOR THE TREATMENT OF ADPKD. THE PHASE1BMAD STUDY IS A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WHICH EVALUATED THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS (PK/PD) OF FARABURSEN IN ADULT PATIENTS WITH ADPKD.

REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

POSITIVE TOPLINE RESULTS FROM AN INTERIM ANALYSIS OF THE FOURTH COHORTOF PATIENTS IN THE PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) AGREEMENT ON KEY COMPONENTS OF A PHASE 3 SINGLE PIVOTAL TRIAL FOR POTENTIAL ACCELERATED APPROVAL WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SAN DIEGO , MARCH 13, 2025 /PRNEWSWIRE/ --REGULUS THERAPEUTICS INC . (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A CORPORATE UPDATE.

REGULUS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND RECENT UPDATES

SAN DIEGO , MARCH 4, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE LEERINK PARTNERS 2025 GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, MARCH 11 TH AT 3:40 P.M. ET. THE LIVE EVENT AND REPLAY OF THE PRESENTATION WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" THROUGH THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.REGULUSRX.COM/EVENTS AND ARCHIVED FOR 90 DAYS FOLLOWING THE PRESENTATION DATE.

REGULUS THERAPEUTICS TO PRESENT AT THE LEERINK PARTNERS 2025 GLOBAL HEALTHCARE CONFERENCE

SAN DIEGO , FEB. 4, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE ON TUESDAY, FEBRUARY 11 TH AT 2:40 P.M. ET. THE LIVE EVENT AND REPLAY OF THE PRESENTATION WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" THROUGH THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.REGULUSRX.COM/EVENTS AND ARCHIVED FOR 90 DAYS FOLLOWING THE PRESENTATION DATE.

REGULUS THERAPEUTICS TO PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE LIFE SCIENCES CONFERENCE

TOPLINE DATA FROM AN INTERIM ANALYSIS OF THE FOURTH COHORT OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL SHOWED CONTINUED MECHANISTIC DOSE RESPONSE EXPLORATORY RESULTS OF IMAGING-BASED BIOMARKERS CONTINUED TO SHOW REDUCTION IN HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME (HTTKV) GROWTH RATE SUCCESSFUL END-OF-PHASE 1 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) WITH AGREEMENT ON KEY COMPONENTS OF A PHASE 3 SINGLE PIVOTAL TRIAL FOR POTENTIAL ACCELERATED APPROVAL COMPANY TO HOLD CONFERENCE CALL AT 8:30 A.M. ET TODAY SAN DIEGO , JAN.29, 2025 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED POSITIVE CLINICAL AND REGULATORY UPDATES FROM ITS ADPKD PROGRAM.

REGULUS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL AND REGULATORY UPDATES FROM ITS AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PROGRAM FOR FARABURSEN (RGLS8429)

SAN DIEGO , NOV. 26, 2024 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: EVERCORE 7TH ANNUAL HEALTHCONX CONFERENCE: FIRESIDE CHAT ON TUESDAY, DECEMBER 3, 2024, AT 3:50 P.M. ET PIPERSANDLER 36TH ANNUAL HEALTHCARE CONFERENCE: PRESENTATION ON WEDNESDAY, DECEMBER 4, 2024, AT 11:10 A.M.

REGULUS THERAPEUTICS ANNOUNCES PARTICIPATION AT UPCOMING HEALTHCARE INVESTMENT CONFERENCES

COMPLETED ENROLLMENT IN THE FOURTH COHORT OF THE PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PRESENTED A POSTER HIGHLIGHTING DATA FROM THE ONGOING MAD STUDY OF RGLS8429 IN ADPKD AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK ON TRACK FOR AN END-OF-PHASE 1 MEETING BY YEAR-END ENDED THIRD QUARTER 2024 WITH CASH, CASH EQUIVALENTS, AND INVESTMENTS OF$87.3 MILLION;CASH RUNWAY INTO H1 2026 SAN DIEGO , NOV. 7, 2024 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY REPORTED FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024. "WE HAVE REMAINED FOCUSED ON RAPIDLY PROGRESSING RGLS8429 FOR THE POTENTIAL TREATMENT OF ADPKD AND WERE PLEASED TO ANNOUNCE THE COMPLETION OF ENROLLMENT IN OUR FOURTH AND FINAL COHORT OF THE PHASE 1B MAD STUDY LAST MONTH.

REGULUS THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT UPDATES

SAN DIEGO , OCT. 8, 2024 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED IT HAS COMPLETED ENROLLMENT OF 26 PATIENTS IN THE FOURTH COHORT IN THE PHASE 1B MAD STUDY OF RGLS8429 FOR THE TREATMENT OF ADPKD. "THE COMPLETION OF ENROLLMENT OF OUR FINAL COHORT MARKS AN IMPORTANT MILESTONE AS WE NEAR THE END OF OUR PHASE 1B STUDY.

REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

SAN DIEGO , AUG. 28, 2024 /PRNEWSWIRE/ -- REGULUS THERAPEUTICS INC. (NASDAQ: RGLS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF INNOVATIVE MEDICINES TARGETING MICRORNAS (THE "COMPANY" OR "REGULUS"), TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: WELLS FARGO HEALTHCARE CONFERENCE: FIRESIDE CHAT ON WEDNESDAY, SEPTEMBER 4, 2024, AT 2:15P.M. ET H.C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE: FIRESIDE CHAT ON MONDAY, SEPTEMBER 9, 2024, AT 10:00 A.M.

Regulus Therapeutics Inc.

RGLS

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

Regulus Therapeutics Inc.

RGLS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Press Releases

RGLS